Epicertin (EPT) is a new ulcerative colitis (UC) drug candidate derived from the nontoxic component of Vibrio cholerae cholera toxin. We have recently shown that oral administration of EPT in mice induces mucosal healing in the colon mediated by transforming growth factor (TGFβ). Here, we investigate EPT’s mucosal healing mechanism and its therapeutic potential in in vitro, in vivo, and ex vivo models.